This suggests that RetSat in retinol metabolism pathway is emerging as a promising therapeutic target for ESCC, and atRA has a potential role in therapy and chemoprevention of patients with ESCC and Barrett’s esophagus. The gene discussed is RETSAT; the disease is esophageal squamous cell carcinoma.